Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
4.170
-0.130 (-3.02%)
At close: May 12, 2025, 4:00 PM
4.010
-0.160 (-3.84%)
After-hours: May 12, 2025, 4:20 PM EDT
Evotec SE Revenue
Evotec SE had revenue of 199.98M EUR in the quarter ending March 31, 2025, a decrease of -4.19%. This brings the company's revenue in the last twelve months to 788.22M, up 1.50% year-over-year. In the year 2024, Evotec SE had annual revenue of 796.97M with 1.99% growth.
Revenue (ttm)
788.22M EUR
Revenue Growth
+1.50%
P/S Ratio
1.70
Revenue / Employee
166,291 EUR
Employees
4,740
Market Cap
1.45B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
Dec 31, 2022 | 751.45M | 133.41M | 21.59% |
Dec 31, 2021 | 618.03M | 117.11M | 23.38% |
Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
EVO News
- 5 days ago - Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments - Accesswire
- 6 days ago - Evotec SE (EVO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment - Accesswire
- 13 days ago - Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025 - Accesswire
- 18 days ago - Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb - Accesswire
- 25 days ago - Evotec SE (EVO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results - Accesswire
- 4 weeks ago - Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025 - Accesswire